计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P649739-1mg |
1mg |
期货 ![]() |
| |
| P649739-5mg |
5mg |
期货 ![]() |
| |
| P649739-10mg |
10mg |
期货 ![]() |
| |
| P649739-25mg |
25mg |
期货 ![]() |
|
| 规格或纯度 | ≥98% |
|---|---|
| 英文名称 | PU139 |
| 生化机理 | PU139 是一种强效的泛组蛋白乙酰转移酶(HAT)抑制剂。PU139 可阻断 HATs Gcn5、p300/CBP 相关因子 (PCAF)、CREB(cAMP 反应元件结合)蛋白 (CBP) 和 p300,其 IC 50 s 分别为 8.39、9.74、2.49 和 5.35 μM |
| 储存温度 | 2-8°C储存,干燥 |
| 运输条件 | 冰袋运输 |
| 作用类型 | 抑制剂 |
| 产品介绍 |
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC 50 s of 8.39, 9.74, 2.49 and 5.35 μM, respectively In Vitro PU139 inhibits cell growth with GI 50 s of <60 μM (A431, A549, A2780, HepG2, SW480, U-87 MG, HCT116 and SK-N-SH and MCF7 cells). PU139 (0-100 μM; 24-72 hours) triggers caspase-independent cell death in the neuroblastoma cell line SK-N-SH. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo PU139 (25 mg/kg; i.p.) synergizes with Doxorubicin used as a prototypic chemotherapeutic drug in growth inhibition . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male NMRI:nu/nu mice (Neuroblastoma xenografts) Dosage: 25 mg/kg Administration: Intraperitoneally (PU139) with Dxorubicin at 8 mg/kg i.v.; Administered on days 14 and 21 as a single dose of each compound or, for combination therapy; both drugs were administered successively within 1 h. Result: Optimum growth inhibition following a single PU139 therapy was moderate, but significant as compared with the untreated group and confirmed the previous findings. Form:Solid IC50& Target:GCN5 8.39 μM (IC 50 ) CREBBP 2.49 μM (IC 50 ) PCAF 9.74 μM (IC 50 ) p300 5.35 μM (IC 50 ) |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | 2-(4-fluorophenyl)-[1,2]thiazolo[5,4-b]pyridin-3-one |
| INCHI | 1S/C12H7FN2OS/c13-8-3-5-9(6-4-8)15-12(16)10-2-1-7-14-11(10)17-15/h1-7H |
| InChi Key | QMCIVCACYJRAAY-UHFFFAOYSA-N |
| Smiles | C1=CC2=C(N=C1)SN(C2=O)C3=CC=C(C=C3)F |
| Isomeric SMILES | C1=CC2=C(N=C1)SN(C2=O)C3=CC=C(C=C3)F |
| PubChem CID | 9992116 |
| 分子量 | 246.26 |
| 溶解性 | DMSO : 10 mg/mL (40.61 mM; ultrasonic and warming and heat to 60°C) |
|---|---|
| 分子量 | 246.260 g/mol |
| XLogP3 | 2.400 |
| 氢键供体数Hydrogen Bond Donor Count | 0 |
| 氢键受体数Hydrogen Bond Acceptor Count | 4 |
| 可旋转键计数Rotatable Bond Count | 1 |
| 精确质量Exact Mass | 246.026 Da |
| 单同位素质量Monoisotopic Mass | 246.026 Da |
| 拓扑极表面积Topological Polar Surface Area | 58.500 Ų |
| 重原子数Heavy Atom Count | 17 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 307.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |